References
- 1. Zeng Y, Katsanis E. The complex pathophysiology of acquired aplastic anemia. Clin Exp Immunol. 2015;180(3):361-70. DOI: 10.1111/cei.12605
- 2. Fong AM, Alam SM, Imai T, Haribabu B, Patel DD. CX3CR1 tyrosine sulfation enhances fractalkine-induced cell adhesion. J Biol Chem. 2002;277(22):19418-23. DOI: 10.1074/jbc.M201396200
- 3. Kobayashi T, Okamoto S, Iwakami Y, Nakazawa A, Hisamatsu T, Chinen H, et al. Exclusive increase of CX3CR1+CD28-CD4+ T cells in inflammatory bowel disease and their recruitment as intraepithelial lymphocytes. Inflamm Bowel Dis. 2007;13(7):837-46. DOI: 10.1002/ibd.20113
- 4. Jamieson WL, Shimizu S, D’Ambrosio JA, Meucci O, Fatatis A. CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008;68(6):1715-22. DOI: 10.1158/0008-5472.CAN-07-1315
- 5. D´Haese JG, Demir IE, Friess H, Ceyhan GO. Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential. Expert Opin Ther Targets. 2010;14(2):207-19. DOI: 10.1517/14728220903540265
- 6. Olsson B, Ridell B, Carlsson L, Jacobsson S, Wadenvik H. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood. 2008;112(4):1078-84. DOI: 10.1182/blood-2008-02-139402
- 7. Ferretti E, Bertolotto M, Deaglio S, Tripodo C, Ribatti D, Audrito V, et al. A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment. Leukemia. 2011;25(8):1268-77. DOI: 10.1038/leu.2011.88
- 8. Tsai WH, Shih CH, Feng SY, Chang SC, Lin YC, Hsu HC. Role of CX3CL1 in the chemotactic migration of all-trans retinoic acid-treated acute promyelocytic leukemic cells toward apoptotic cells. J Chin Med Assoc. 2014;77(7):367-73. DOI: 10.1016/j.jcma.2014.04.008
- 9. Andreasson U, Ek S, Merz H, Rosenquist R, Andersen N, Jerkeman M, et al. B cell lymphomas express CX3CR1 a non-B cell lineage adhesion molecule. Cancer Lett. 2008;259(2):138-45. DOI: 10.1016/j.canlet.2007.10.031
- 10. Zhao M, Perry JM, Marshall H, Venkatraman A, Qian P, He XC, et al. Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells. Nat Med. 2014;20(11):1321-6. DOI: 10.1038/nm.3706
- 11. Bruns I, Lucas D, Pinho S, Ahmed J, Lambert MP, Kunisaki Y, et al. Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion. Nat Med. 2014;20(11):1315-20. DOI: 10.1038/nm.3707
- 12. Nakamura-Ishizu A, Takubo K, Fujioka M, Suda T. Megakaryocytes are essential for HSC quiescence through the production of thrombopoietin. Biochem Biophys Res Commun. 2014;454(2):353-7. DOI: 10.1016/j.bbrc.2014.10.095
- 13. Heazlewood SY, Neaves RJ, Williams B, Haylock DN, Adams TE, Nilsson SK. Megakaryocytes co-localise with hemopoietic stem cells and release cytokines that up-regulate stem cell proliferation. Stem Cell Res. 2013;11(2):782-92. DOI: 10.1016/j.scr.2013.05.007
- 14. Maciejewski JP, Hibbs JP, Anderson S, Katevas P, Young NS. Bone marrow and peripheral blood lymphocyte phenotype in patients with bone marrow failure. Exp Hematol 1994; 22(11): 1102–10.
- 15. Melenhorst JJ, Van Krieken JH, Dreef E, Landegent JE, Willemze R, Fibbe WE. T cells selectively infiltrate bone marrow areas with residual haemopoiesis of patients with acquired aplastic anaemia. Br J Haematol 1997; 99(3): 517–9. DOI: 10.1046/j.1365-2141.1997.4353245.x
- 16. Ostuni MA, Guellec J, Hermand P, Durand P, Combadiere C, Pincet F, et al. CX3CL1, a chemokine finely tuned to adhesion: critical roles of the stalk glycosylation and the membrane domain. Biol Open. 2014;3(12):1173-82. DOI: 10.1242/bio.20149845
- 17. Fraticelli P, Sironi M, Bianchi G, D´Ambrosio D, Albanesi C, Stoppacciaro A, et al. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001; 107(9): 1173–81. DOI: 10.1172/JCI11517
- 18. Yoneda O, Imai T, Nishimura M, Miyaji M, Mimori T, Okazaki T, et al. Membrane-bound form of fractalkine induces IFN-gamma production by NK cells. Eur J Immunol 2003; 33(1): 53–8. DOI: 10.1002/immu.200390007
- 19. Kordasti S, Marsh J, Al-Khan S, Jiang J, Smith A, Mohamedali A, et al. Functional characterization of CD4+ T cells in aplastic anemia. Blood. 2012;119(9):2033-43. DOI: 10.1182/blood-2011-08-368308
- 20. White GE, Greaves DR. Fractalkine: a survivor’s guide: chemokines as antiapoptotic mediators. Arterioscler Thromb Vasc Biol. 2012;32(3):589-94. DOI: 10.1161/ATVBAHA.111.237412
- 21. Ren J, Hou XY, Ma SH, Zhang FK, Zhen JH, Sun L, et al. Elevated expression of CX3C chemokine receptor 1 mediates recruitment of T cells into bone marrow of patients with acquired aplastic anaemia. J Intern Med. 2014;276(5):512-24. DOI: 10.1111/joim.12218
- 22. Morita Y, Matsuda M, Hanamoto H, Shimada T, Tatsumi Y, Maeda Y, et al. A perforin/granzyme-positive MDS-derived T cell line, K2-MDS, induces apoptosis in CD34+ cells through the fractalkine-CX3CR1 system. Clin Immunol. 2004;113(1):109-16. DOI: 10.1016/j.clim.2004.05.005
- 23. Risitano AM. Aplastic Anemia: Alternative Immunosuppressive Treatments and Eltrombopag. A report from the 2014 EBMT Educational Meeting from the Severe Aplastic Anaemia and Infectious Diseases Working Parties. Curr Drug Targets. 2015; 14(3):206-12.